What's new?
Added 21 days ago Drug news
Alnylam announces new and enhanced framework for value-based agreements to accelerate patient and provider access to Givlaari.
Alnylam Pharmaceuticals, Inc. announces a new and enhanced framework for value-based agreements (VBAs) designed to help patients with acute hepatic...
Added 2 hours ago Drug news
European Commission approves Evenity for severe osteoporosis.- Amgen + UCB
Amgen and UCB announced that the European Commission has granted marketing authorization for Evenity (romosozumab) for the treatment of severe...
Added 2 hours ago Drug news
Kite/Gilead submits BLA to FDA for KTE X19 to treat relapsed or refractory mantle cell lymphoma.
Kite, a Gilead Company announced that it has submitted a Biologics License Application (BLA) to the FDA for the investigational...
Added 2 hours ago Drug news
Phase III FeDeriCa study of Perjeta + Herceptin meets secondary endpoint in breast cancer.- Genentech/Roche + Halozyme Therapeutics
Halozyme Therapeutics announced that new data from the global phase III FeDeriCa study conducted by Genentech/Roche will be presented at...
Added 2 hours ago Drug news
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal phase II HER2-positive metastatic breast cancer trial (DESTINY-Breast01).- Daiichi Sankyo + AstraZeneca
Daiichi Sankyo presented positive detailed data from the global pivotal phase II single-arm DESTINY-Breast01 trial of DS-8201 ([fam-] trastuzumab deruxtecan),...
Added 2 hours ago Drug news
Positive tucatinib HER2CLIMB trial results in locally advanced or metastatic HER2-positive breast cancer published in the NEJM Seattle Genetics
Seattle Genetics, Inc. announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer...
Added 1 day ago Drug news
Follow up of MAIA Trial of Darzalex + lenalidomide + dexamethasone in patients with newly diagnosed multiple myeloma who are transplant ineligible are presented at ASH Meeting.- Janssen Biotech + Genmab A/S
Data from the follow-up (median of 36.4 months) of the Phase III MAIA study (Abstract #1875) was presented at ASH...